Dr. Reddy’s Laboratories kicked off the fiscal year on a solid note, posting its Q1 FY26 results with a healthy revenue increase but a slight dip in margins. The Hyderabad-based pharma giant reported a net profit of ₹1,417.8 crore, up 1.8% from ₹1,392 crore in the same quarter last year.
Revenue for the quarter stood at ₹8,545 crore, marking a strong 11.4% year-on-year (YoY) growth compared to ₹7,672.7 crore in Q1 FY25. The company’s operating performance also showed improvement, with EBITDA rising 5% YoY to ₹2,278 crore, up from ₹2,160 crore in the previous year.
However, the EBITDA margin contracted to 26.7%, compared to 28.2% in Q1 FY25, indicating cost pressures or product mix changes impacting profitability.
One key weak spot was in the North American market, where sales declined by 11% YoY to ₹3,410 crore, down from ₹3,846 crore. This drop may reflect pricing pressure and competitive dynamics in the generics space.
In the meantime, Dr Reddy’s Laboratories shares closed at ₹1,248.00 today, slightly higher than the opening price of ₹1,240.20. The stock touched an intraday high of ₹1,252.10 and a low of ₹1,231.00 during the session. Over the past year, the stock has seen a 52-week high of ₹1,421.49 and a low of ₹1,020.00.
